Brendan M Everett

List of Publications by Citations

65 papers	9,604 citations	34 h-index	73 g-index
73 ext. papers	13,425 ext. citations	12.7 avg, IF	5.89 L-index

#	Paper	IF	Citations
65	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *New England Journal of Medicine*, **2017**, 377, 1119-1131	59.2	3877
64	Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2017**, 390, 1833-1842	40	634
63	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. *New England Journal of Medicine*, **2019**, 380, 752-762	59.2	538
62	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet, The*, **2018**, 391, 319-328	40	430
61	Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. *Circulation*, **2012**, 126, 2739-48	16.7	374
60	Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. *American Heart Journal*, **2013**, 166, 199-207.e15	4.9	276
59	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *European Heart Journal*, **2018**, 39, 3499-3507	9.5	233
58	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *New England Journal of Medicine*, **2021**, 385, 777-789	59.2	227
57	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. *Circulation*, **2019**, 139, 1289-1299	16.7	223
56	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *New England Journal of Medicine*, **2021**, 385, 790-802	59.2	203
55	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. *American Heart Journal*, **2018**, 206, 80-93	4.9	183
54	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *Journal of the American College of Cardiology*, **2018**, 72, 3200-3223	15.1	180
53	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. *Journal of the American College of Cardiology*, **2018**, 71, 2392-2401	15.1	170
52	Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. *European Heart Journal*, **2016**, 37, 2428-37	9.5	140
51	Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). *Circulation*, **2010**, 121, 143-50	16.7	135
50	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. *Journal of the American College of Cardiology*, **2020**, 76, 1117-1145	15.1	124
49	Inhibition of Interleukin-1 by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. *Journal of the American College of Cardiology*, **2018**, 71, 2405-2414	15.1	114

48	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 840-9	18.1	108
47	Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. *Journal of the American College of Cardiology*, **2014**, 63, 1200-1210	15.1	102
46	Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. *Circulation*, **2015**, 131, 528-35	16.7	99
45	Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. *New England Journal of Medicine*, **2015**, 373, 1588-91	59.2	97
44	The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. *Journal of the American College of Cardiology*, **2006**, 48, 2235-42	15.1	97
43	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. *BMJ, The*, **2018**, 360, k119	5.9	93
42	Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the WomenTs Health Study. *Circulation*, **2011**, 123, 2811-8	16.7	86
41	High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. *Circulation*, **2015**, 131, 1851-60	16.7	80
40	Physical activity and the risk of incident atrial fibrillation in women. *Circulation: Cardiovascular Quality and Outcomes*, **2011**, 4, 321-7	5.8	74
39	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. *Diabetes Care*, **2019**, 42, 2298-2306	14.6	70
38	Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. *Annals of Thoracic Surgery*, **2007**, 83, 592-7	2.7	61
37	Novel Antiatherosclerotic Therapies. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 538-545	9.4	58
36	Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. *Annals of Internal Medicine*, **2020**, 172, 369-380	8	52
35	Relationship of Interleukin-1 Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. *Annals of Internal Medicine*, **2018**, 169, 535-542	8	51
34	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2017**, 69, 1823-1831	9.5	44
33	Inhibition of Interleukin-1 and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. *Journal of the American College of Cardiology*, **2020**, 76, 1660-1670	15.1	43
32	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 326, 1703-1712	27.4	36
31	Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. *Atherosclerosis*, **2009**, 202, 282-8	3.1	27

30	Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. *Clinical Therapeutics*, **2008**, 30, 661-72	3.5	26
29	B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. *Journal of the American College of Cardiology*, **2014**, 64, 1789-97	15.1	20
28	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.. *JAMA - Journal of the American Medical Association*, **2022**, 327, 227-236	27.4	18
27	Hypoglycemia and Elevated Troponin in Patients With Diabetes and Coronary Artery Disease. *Journal of the American College of Cardiology*, **2018**, 72, 1778-1786	15.1	18
26	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. *JAMA Internal Medicine*, **2020**, 180, 141-144	11.5	14
25	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. *Seminars in Arthritis and Rheumatism*, **2019**, 48, 840-846	5.3	12
24	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. *Seminars in Arthritis and Rheumatism*, **2019**, 49, 389-395	5.3	11
23	Dyslipidemia Profiles in Patients with Peripheral Artery Disease. *Current Cardiology Reports*, **2019**, 21, 42	4.2	11
22	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. *American Journal of Hypertension*, **2016**, 29, 1117-24	2.3	11
21	Targeting Inflammation to Reduce Residual Cardiovascular Risk. *Current Atherosclerosis Reports*, **2020**, 22, 66	6	11
20	Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population. *Arthritis Care and Research*, **2019**, 71, 104-115	4.7	10
19	Comparative Risks of Cardiovascular Disease in Patients With Systemic Lupus Erythematosus, Diabetes Mellitus, and in General Medicaid Recipients. *Arthritis Care and Research*, **2020**, 72, 1431-1439	4.7	9
18	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. *American Journal of Cardiology*, **2016**, 117, 376-81	3	9
17	Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis. *Arthritis and Rheumatology*, **2018**, 70, 1392-1398	9.5	8
16	Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. *Rheumatology*, **2020**, 59, 495-504	3.9	8
15	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. *Annals of Internal Medicine*, **2021**, 174, 1528-1541	8	8
14	Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores. *Rheumatology International*, **2020**, 40, 257-261	3.6	7
13	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. *BMJ, The*, **2020**, 370, m2812	5.9	6

List of Publications

12	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2020**, 47, 1359-1365	4.1	6
11	Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death. *Circulation*, **2020**, 142, 1148-1158	16.7	6
10	Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations. *Trends in Cardiovascular Medicine*, **2017**, 27, 41-47	6.9	5
9	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. *Diabetes Care*, **2020**, 43, 2684-2690	14.6	3
8	Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death. *Circulation*, **2016**, 134, 773-5	16.7	3
7	Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". *Circulation*, **2014**, 130, e152	16.7	2
6	Using inflammatory biomarkers to guide lipid therapy. *Current Cardiovascular Risk Reports*, **2008**, 2, 29-34	6.9	2
5	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. *European Journal of Heart Failure*, **2021**,	12.3	2
4	Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. *Rheumatology*, **2021**, 60, 3789-3798	3.9	1
3	Reply: Inflammatory Pathways in CVD and Diabetes: Broad-Spectrum Versus Selective Targeting. *Journal of the American College of Cardiology*, **2018**, 72, 1432-1433	15.1	0
2	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. *Annals of Internal Medicine*, **2022**, 175, W4	8	
1	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. *Annals of Internal Medicine*, **2022**, 175, W4-W5	8	